

Review on Various Type of Vaccines for Controlling Infectious Disease

Anamika¹, Deepshikha Jamloki², Roshan Kumar³

How to cite this article:

Anamika, Deepshikha Jamloki *et al.*, Review on Various Type of Vaccines for Controlling Infectious Disease. Indian J Comm Dis. 2024;10(2):55–61.

Abstract

Background: Vaccines have played a critical role in the prevention and treatment of infectious diseases, greatly lowering worldwide morbidity and mortality. This review examines many forms of vaccinations. In contrast, inactivated vaccines, such as the polio vaccine, are safer for immunocompromised people, they frequently require booster shots.

Aim: This review emphasises the importance of vaccinations in public health and the need for innovation to tackle future infectious disease threats. The introduction of new pathogens has prompted the creation of novel vaccination platforms, including mRNA and viral vector vaccines. mRNA vaccines, such as those used to treat COVID-19, use genetic instructions to direct cells to manufacture antigens, resulting in strong immunity.

Conclusion: These vaccines have demonstrated excellent efficacy and rapid scaling, making them valuable instruments in pandemics. This review emphasises the necessity of designing vaccine methods that meet individual illnesses, demographics, and logistical obstacles. While vaccinations have considerably reduced the occurrence of infectious diseases, more research is needed to address future threats, improve vaccine efficacy, and overcome obstacles such as vaccine reluctance and global inequities. Understanding the capabilities and limits of each vaccine type will help researchers and policymakers better equip healthcare systems to address current and future infectious disease concerns.

Keywords: Vaccines, Infectious disease, COVID-19, Nanoparticle

INTRODUCTION

Pathogenic microorganisms such as bacteria, viruses, parasites, or fungus cause infectious diseases, which can be transmitted from one person to another, either directly or indirectly. Infections are a primary cause of death in the global

population. Measles affects around 20 million people each year, especially in underdeveloped countries in Africa and Asia. Smallpox killed between 300 and 500 million people in the 20th century.¹ The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that caused the coronavirus disease 2019 (COVID-19) pandemic engulfed the entire world in less than 6 months,

Author's Affiliation: ^{1,3}Research Scholar, Maharaja Agrasen University, Barotiwala, Himachal Pradesh 174103, India, ²Assistant Professor, Shree Dev Bhoomi Institute of Education Science and Technology, Dehradun, Majhaun, Uttarakhand 248007, India.

Corresponding Author: Anamika, Research Scholar, Maharaja Agrasen University, Barotiwala, Himachal Pradesh 174103, India.

E-mail: bhagatanamika63@gmail.com

Received on: 18.11.2024

Accepted on: 27.12.2024



This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0.

with high mortality rates among the elderly and those with comorbidities. The pandemic has significantly impacted the global economy. Short of lockdowns, the sole means of control have been a succession of imperfect and limiting mitigation measures such as self-distancing, mask use, travel limitations, and avoiding gatherings. With over 100 million individuals sick and over 2 million deaths, it appears that adding vaccine(s) to existing counter measures is the best hope for pandemic containment. Taken together, these considerations require researchers and policymakers to be attentive, re-examine the approach to surveillance and management of emerging infectious disease threats, and rethink global systems for pandemic disease control.²

Vaccines are biological substances designed to stimulate and prepare the immune system for infection or disease. They rely on the highly evolved mammalian immune system to recognise, respond to, and recall infections. Antigens obtained from the pathogen of interest or bio-manufactured are the primary components of vaccinations. Preservatives, stabilisers, excipients, and residues of ingredients carried over from the production process are all possible additions. Adjuvants are frequently added to boost immunogenicity (ability to trigger an immune response) and efficacy in some populations (e.g., newborns, elderly, and immuno compromised adults), as well as to allow antigen dose sparing (raise the global supply of vaccines).³




Fig. 1: Schematic representation of common vaccine components, showing the typical vaccine components, including the active ingredients, stabilizers, adjuvants, preservatives, antibiotics, and trace components

Vaccination has a significant impact on the health of the world's population. With the exception of potable water, no other technique has had such a significant impact on mortality reduction and population increase. One of the most important scientific accomplishments of the twenty-first century has been the discovery of safe and effective vaccines against illnesses that cause significant morbidity and mortality. Vaccination, along with sanitation and safe drinking water, are public health policies that have unquestionably improved health outcomes over the world. Vaccines are projected to have avoided 6 million deaths from vaccine-preventable diseases per year.⁴ Vaccination is the most effective means of preventing infectious illnesses. Vaccination is the procedure of delivering a biological substance to a

recipient's immune system in order to induce the production of antibodies or other modifications that will provide future protection against specific infectious diseases. Vaccination is regarded the most successful and cost-effective medical intervention ever developed, and it can be generated from living modified organisms, inactivated or killed organisms, extracted cellular fractions, toxins, or a mix of these forms.⁶

History of vaccine for controlling infectious disease:

Although inoculation procedures date back over 500 years, Edward Jenner coined the word vaccine in the 18th century. It is derived from the Latin word *vacca*, which means cow. Jenner infected an 8-year-old kid with cowpox lesions from milkmaids'

hands in 1796. This ultimately provided immunity against smallpox. After 80 years, Louis Pasteur was important in developing a highly effective live attenuated rabies vaccination for humans. In the nineteenth century, we saw the evolution of germ theory through the discovery of several microbes by Koch.⁷ This era saw the development of novel pathogen vaccinations as well as substantial global study. Vaccines against rabies, typhoid, diphtheria, tuberculosis, tetanus, and pertussis were developed and marketed until 19308, 9. According to Louis Pasteur's key discovery on propagating the virus in chicken embryos, a new age of mass vaccine production began in 1931, using a combination of procedures. From 1930 to 1950, particularly during World War II, military aims provided strong motivation for vaccine research. Furthermore, from that point forward, foundations and state entities such as WHO and research institutes provided major funding. Vaccines such as Polio, Japanese Encephalitis B, and Influenza were developed during this time. Following World War II, focused immunisation programmes became a universal technique for improving public health.¹⁰ Currently, over 20 vaccinations against infectious illnesses are widely utilised around the world to prevent human infections. Although this is significant, that comparison to the number of infectious diseases that currently affect humans and animals worldwide, highlighting significant knowledge gaps in specific pathogens, immunopathology, and the complex interplay between pathogens and hosts. As a result, several diseases that are prevalent globally, despite still do not have an effective vaccination accessible or even a pre-clinical or clinical study in progress.¹¹ During the COVID-19 pandemic, nucleic acid-based vaccines were the most current and innovative innovation to vaccine development. Pfizer and Moderna's mRNA-based coronavirus vaccine, launched at the end of 2020, is regarded as one of the most significant advances in vaccine research. The global use of mRNA-based vaccines during the pandemic demonstrated the technology's safety and reliability. This is significant because it demonstrates the public's acceptance of technology and encourages further research and development in mRNA-based vaccinations. Surprisingly, this method has become quite important in vaccine development. As a result, in a few years, multiple mRNA-based vaccines have entered different stages of clinical trial.¹²

Types of Vaccines:

- a. **Inactivated vaccines:** Some vaccines, such as those for influenza, cholera, polio, bubonic

plague, hepatitis A, and rabies, include inactivated but once virulent microorganisms that have been eliminated by chemicals, heat, radiation, and antibiotics.¹³

- b. **DNA Vaccines:** For Example: Ongoing Phase 2/3 trials such as GX-19 (Genexine, Inc.) and INO-4800 (International Vaccine Institute; Inovio Pharmaceuticals) Canada—COVID-19 Symvivo (AnGes, Inc.)" Plasmids can enter B cell nuclei, which is required for the synthesis of RBD or S proteins. This type of DNA vaccination has several benefits, including the ability to be freeze-dried, stored for a long time, and transferred at room temperature (unlike ultra-fragile mRNA vaccines) and the elimination of the need to transport the live virus during preparation. Despite being in phase 3 testing, certain plasmid-derived DNA vaccines still lack a general use licence. At the moment, only veterinary use is permitted for DNA vaccines.¹⁴
- c. **Live-Attenuated, or Replication-Competent Attenuated Vaccines:** Vaccines known as live attenuated or replication-competent attenuated vaccines are made from viruses that have been weakened, meaning that the virulence of the disease is significantly decreased. But the attenuated viruses can still infect, multiply, and release within the host, just like a real infection. A crucial factor in this technology's design is its capacity to sustain the viruses' capacity for replication without resulting in illness or a return to infectiousness.¹⁵
- d. **Virus-like Particles (VLPs) Vaccines:** Virus-like Particles (VLPs) are collections of macromolecules that are made to resemble a native virus in terms of size, shape, and surface epitopes. VLPs can be classified according to the number of protein layers that make up the rigid structure known as the capsid and whether or not a lipid envelope is present.¹⁶ VLP-derived vaccines are commonly made in bioreactors following transfection of insect, yeast, bacterial, plant, or mammalian cells with one or several genetic constructs. At least two structural elements of the original virus are encoded by the constructs, enabling self-assembly into particles incapable of replication.¹⁷ The addition of immunogenic/dominant peptides and/or adjuvants, surface chemical changes, or the selection of the VLP system can all be used in the immunogenicity of VLPs during the design and production stages. Targeted surface modifications with

straightforward chemistries increase potency, alter tropism, and enable the technology to be repurposed for a variety of uses, including chemical catalysis, imaging (such as Positron Emission Tomography and Magnetic Resonance Imaging), and targeted drug or nucleic acid delivery.¹⁸

Why Vaccines is important for chronic and acute diseases:

The World Health Organisation now recommends this vaccine for use in infant immunization programs worldwide. A successful immunization program that achieves a high coverage rate is also likely to decrease infectious agent transmission, which will result in herd immunity and increase the program's total impact. These kind of vaccine would appear very appealing for preventing infections that result in the many types of chronic illnesses that bacteria can cause, indicating that multiple vaccination tactics will be required. These can be classified into one of two main categories: treating the persistent infection or preventing the initial acute infection.

The prevention of acute infection has numerous benefits. It would be consistent with the existing concept of vaccination. Vaccine development would be uncomplicated up to and including the clinical efficacy trial, which would measure the prevention of acute infection. As a result, one does not have to be concerned with the pathophysiology of the chronic disease. This strategy has proven successful for the hepatitis B vaccine (decrease of chronic hepatitis and liver cancer in 10 years after infancy vaccination). The chronic disease relatively early in life, e.g., for juvenile diabetes, if the connection to the infectious agent is established and a vaccine available.¹⁹

A chronic disease, according to the World Health Organisation (WHO), is one that lasts for a long time, progresses slowly, and cannot be transferred from one person to another. 38 million people die from chronic illnesses every year. The CDC recommends no vaccines specifically for those with addiction, arthritis, autism, osteoporosis, and various psychotic disorders, despite the fact that these conditions are considered chronic and impact thousands of adults annually. People suffering from these conditions should consult their doctor about immunisations that are acceptable for their lifestyle. The WHO classifies non-communicable illnesses into four categories: cardiovascular disease (17.5 million deaths per year), cancer (8.2 million), chronic respiratory disease (4 million), and diabetes (1.5 million). The CDC does

recommend extra immunizations for patients with these conditions because of the consequences that may occur when both the chronic disease and the vaccine preventable disease are present inside the body.²⁰

Reduction in Infectious Diseases Morbidity and Mortality

The most significant impact of vaccines has been to prevent morbidity and mortality from serious infections that disproportionately affect children. Vaccines are estimated to prevent almost six million deaths/year and to save 386 million life years and 96 million disability-adjusted life years (DALYs) globally. The traditional measures of vaccine impact include: vaccine efficacy, the direct protection offered to a vaccinated group under optimal conditions e.g., trial settings; or vaccine effectiveness, the direct and indirect effect of vaccines on the population in a real-life setting. Providing a numerical measure of vaccine impact therefore involves estimating the extent of morbidity and mortality prevented. Vaccines have had the biggest impact in reducing morbidity and mortality from severe illnesses that disproportionately affect children. Worldwide, vaccinations are thought to save 386 million life years, 96 million disability-adjusted life years (DALYs), and about six million deaths annually. The direct protection provided to a vaccinated group under ideal circumstances, such as trial settings, is known as vaccine efficacy. Alternatively, the direct and indirect influence of vaccinations on the population in a real-world situation is known as vaccine effectiveness. Therefore, measuring the amount of morbidity and mortality avoided is necessary to provide a numerical estimate of vaccine impact.²¹

Role of Nanoparticles in Vaccines development:

In vaccine formulations, nanoparticles (NPs) have been utilised more than any other kind of nanomaterial. Typically, vaccine delivery nanoparticles consist of three components: the material or materials that make up the nanoparticle, such as natural or synthetic polymers, inorganic substances, lipids, etc.; immunogen or immunomodulatory agents, such as DNA vaccines, siRNA, cytokines, etc.; and, lastly, targeting and immunostimulatory ligands that are added to the particle surface, such as tissue-specific ligands, immune-specific ligands, pathogen associated molecular patterns (PAMPs), etc. Important functions of the NP material composition include transport, intracellular trafficking, cellular uptake, and the NPs' biodegradability and biocompatibility.²²

The utilisation of nanoparticles coated with antigens and adjuvants shows great promise for producing next-generation vaccinations. These coated nanoparticles have increased stability, immunogenicity, and targeting capacity, resulting in greater immune responses to numerous infections and malignancies. Nanoparticle-coated vaccines are emerging in the realm of immunisation. The following recent research illustrate the rise of nanoparticle-coated vaccines and offer useful insights into future vaccine design and development. Smith *et al.* discuss the use of lipid-based nanoparticles coated with viral antigens to generate COVID-19 vaccines. The author demonstrates that these coated nanoparticles generate robust immunological responses, including the formation of neutralising antibodies and T-cell activation, resulting in increased protection against SARS-CoV-2 infection.²³

In another study, Johnson *et al.* describes the application of polymer-coated nanoparticles for malaria vaccine development. The researchers demonstrate that these coated nanoparticles can effectively deliver multiple antigen components, resulting in a potent immune response and long-lasting protection against *Plasmodium falciparum* infection in preclinical models.²⁴

Impact of Vaccine in community health:

“The impact of vaccination on the health of the world’s peoples is hard to exaggerate. With the exception of safe water, no other modality has had such a major effect on mortality reduction and population growth”²⁵. One of the most important scientific accomplishments of the twenty-first century has been the discovery of safe and effective vaccines against illnesses that cause significant morbidity and mortality. Vaccination, along with sanitation and safe drinking water, are public health policies that have unquestionably improved health outcomes over the world. Vaccines are believed to have avoided 6 million deaths from vaccine-preventable diseases each year.²⁶ The world’s population is predicted to approach 10 billion people by 2055²⁷ because to efficient vaccines that reduce the risk of disease and increase life expectancy on every continent. However, much work remains to guarantee the funding, supply, distribution, and administration of vaccines to all populations, especially those that are hard to reach, such as those who doubt their protective benefit and those who live amid civil disruption. The expansion of vaccine benefits to everyone has been made possible by the various funding streams of organisations such as the World Health Organisation (WHO), United Nations Children’s

Fund (UNICEF), Gavi, the Vaccine Alliance, the Bill & Melinda Gates Foundation, and the Coalition for Epidemic Preparedness Initiative (CEPI). Given the health and financial effects of COVID-19 on societies in high-, middle-, and low-income nations, these groups’ significance in international collaboration and involvement was crucial during the 2019 SARS-CoV-2 pandemic. The health, economic, and social fabric benefits of vaccinations will be highlighted in this review. These factors should be taken into account in the overall impact assessment to make sure that vaccines are given priority by those who are making funding decisions.²⁸

CONCLUSION

Vaccines have significantly improved the health of the world by successfully preventing and curing a wide range of infectious diseases. Both conventional live-attenuated and inactivated vaccines as well as innovative mRNA and viral vector platforms have made substantial contributions to lowering the burden and death rate of disease. In order to ensure individualised and effective immune responses, these various vaccination methods address the particular difficulties presented by various diseases and target populations.

By closely resembling natural diseases, live-attenuated vaccines have demonstrated remarkable efficacy in providing strong and durable protection. The possible danger of reactivation, however, limits their usage in immunocompromised people. Booster doses are frequently necessary to maintain protection from inactivated vaccinations, notwithstanding their safety. Because they use specialised pathogen components, subunit and conjugate vaccines provide focused protection with minimal side effects, making them especially appropriate for vulnerable populations like children and the elderly.

The development of mRNA vaccines has signalled a revolution in vaccination technology, as seen by their effectiveness against COVID-19. They are a promising strategy against newly emerging infectious diseases because of their great efficacy and quick development. Similar to this, viral vector vaccines have demonstrated enormous promise by fusing powerful immune activation with safety, particularly in outbreak situations. Notwithstanding these developments, problems still exist, including vaccine reluctance, restricted availability in areas with limited resources, and the appearance of variations that could lessen the effectiveness

of the vaccine. To solve these problems and improve vaccine stability, storage, and delivery, international collaboration, fair distribution methods, and ongoing innovation are needed.

In conclusion, the evolution of vaccines underscores the critical role of scientific innovation in safeguarding public health. The variety of vaccine types ensures adaptability to different diseases and circumstances, while ongoing research aims to overcome existing limitations. As the world continues to face emerging infectious threats, vaccines will remain an indispensable tool for preventing disease, saving lives, and fostering global health security. Strengthening public trust and ensuring equitable access will be crucial to maximising the benefits of these life-saving interventions.

Conflict of Interest: None

Funding: None

Ethics Declaration: None

REFERENCES

1. Baafi J., Darko I.O., Asenso F.W. Vaccination as a control of infectious diseases. *J Appl Computat Math.* 2017; 6(357):
2. Excler J.L., Saville M., Berkley S., Kim J.H. Vaccine development for emerging infectious diseases. *Nature medicine.* 2021 Apr;27(4):591-600.
3. Ghattas M., Dwivedi G., Lavertu M., Alameh M.G. Vaccine technologies and platforms for infectious diseases: Current progress, challenges, and opportunities. *Vaccines.* 2021 Dec 16;9(12):1490.
4. Rodrigues C.M., Plotkin S.A. Impact of vaccines; health, economic and social perspectives. *Frontiers in microbiology.* 2020 Jul 14; 11:1526.
5. elochukwu ic, okoro o, unekwe p, irinmwinnuwa e. role of vaccines in prevention of diseases: a review.
6. Berkeley S. improving access to vaccine through tiered pricing. *Lancet* 383, 2018: 2256-2267.
7. Saleh A., Qamar S., Tekin A., Singh R., Kashyap R. Vaccine development throughout history. *Cureus.* 2021 Jul; 13(7).
8. Wever P.C., van Bergen L. Prevention of tetanus during the First World War. *Med Humanit.* 2012; 38(2):78-82.
9. Rappuoli R., Malito E. History of Diphtheria Vaccine Development. *Corynebacterium diphtheriae and Related Toxigenic Specie.* Springer; 2014. p. 225-38.
10. Tahamtan A., Charostad J., Shokouh S.J., Barati M. An overview of history, evolution, and manufacturing of various generations of vaccines. *Journal of Archives in Military Medicine.* 2017 Sep 30; 5(3).
11. Conceição Silva F., De Luca P.M., Lima-Junior J.D. Vaccine development against infectious diseases: State of the art, new insights, and future directions. *Vaccines.* 2023 Oct 25; 11(11):1632.
12. Kumar R. New trends in vaccine characterization, formulations, and development. *Vaccines.* 2024 Mar 20; 12(3):338.
13. Shapiro C.G., Kendrick P., Grace E. Pertussis vaccines emerging infectious; *Journal of medicine,* 339(4), 2010; 209-215.
14. Lotfi H., Mazar M.G., Ei N.M., Fahim M., Yazdi N.S. Vaccination is the most effective and best way to avoid the disease of COVID-19. *Immunity, Inflammation and Disease.* 2023 Aug; 11(8):e946.
15. Mak T.W., Saunders M.E. 23—Vaccines and Clinical Immunization. In: Mak T.W., Saunders M.E., editors. *The Immune Response.* Academic Press; Burlington, MA, USA: 2006. pp. 695-749.
16. Nooraei S., Bahrulolum H., Hoseini Z.S., Katalani C., Hajizade A., Easton A.J., Ahmadian G. Virus-like Particles: Preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. *J. Nanobiotechnology.* 2021;19:59.
17. Ding X., Liu D., Booth G., Gao W., Lu Y. Virus-like Particle Engineering: From Rational Design to Versatile Applications. *Biotechnol. J.* 2018; 13:1700324.
18. Lua L.H.L., Connors N.K., Sainsbury F., Chuan Y.P., Wibowo N., Middelberg A.P.J. Bioengineering Virus-like Particles as vaccines. *Biotechnol. Bioeng.* 2014; 111:425-440.
19. Mäkelä P.H. DEVELOPING VACCINES FOR PREVENTION OF CHRONIC DISEASE. In *The Infectious Etiology of Chronic Diseases: Defining the Relationship, Enhancing the Research, and Mitigating the Effects: Workshop Summary 2004 Jun 16 (p. 175).* National Academies Press.
20. Smith K. Vaccines and chronic disease. *Delaware Journal of Public Health.* 2017 Mar;3(1):46.
21. Rodrigues C.M., Plotkin S.A. Impact of vaccines; health, economic and social perspective. *Frontiers in microbiology.* 2020 Jul 14;11:1526.
22. Hajizade A., Ebrahimi F., Salmanian A.H., Arpanaei A., Amani J. Nanoparticles in vaccine development. *Journal of Applied Biotechnology Reports.* 2014 Dec 1; 1(4):125-34.
23. S. Nooraei *et al.*, "Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers," *J. Nanobiotechnology*, vol. 19, no. 1, Dec. 2021.
24. I. Ielo, G. Rando, F. Giacobello, S. Sfameni, A. C.- Molecules, and undefined 2021, "Synthesis, chemical-physical characterization, and biomedical applications of functional gold nanoparticles: A review," *mdpi.com* Ielo, G Rando, F. Giacobello, S. Sfameni, A. Castellano, M Gall. D. Drommi, G. Rosacea *Molecules*, 2021.

25. Pollard, A.J., Perrett, K.P., and Beverley, P.C. (2009). Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. *Nat. Rev. Immunol.* 9, 213–220.
26. Poovorawan, Y., Chongsrisawat, V., Theamboonlers, A., Leroux-Roels, G., Kuriyakose, S., Leyssen, M., *et al.* (2011). Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region. *J. Viral Hepat.* 18, 369–375.
27. Riumallo-Herl, C., Chang, A.Y., Clark, S., Constenla, D., Clark, A., Brenzel, L., *et al.* (2018). Poverty reduction and equity benefits of introducing or scaling up measles, rotavirus and pneumococcal vaccines in low-income and middle-income countries: a modelling study. *BMJ Glob. Health* 3:e000613.
28. Soergel, P., Makowski, L., Schippert, C., Staboulidou, I., Hille, U., and Hillemanns, P. (2012). The cost efficiency of HPV vaccines is significantly underestimated due to omission of conisation-associated prematurity with neonatal mortality and morbidity. *Hum. Vacc. Immunother.* 8, 243–251.

